Daniel Bohrer was named Executive Vice President of Co-Diagnostics, Inc. As of November 6, 2026, Co-Diagnostics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 4, 2026, naming 1 appointment (Form 8-K, September 4, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Co-Diagnostics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Co-Diagnostics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-04. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Co-Diagnostics, Inc. files it.
Also on the record for Co-Diagnostics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| August 10, 2026 | Stake report, Schedule 13G/A, by JANE STREET GROUP, LLC | 1.7% of the class | 5%+ stakes | Source |
| June 3, 2026 | Stake report, Schedule 13G, by JANE STREET GROUP, LLC | 6.4% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G/A, by Ayrton Capital LLC | — | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G, by Ayrton Capital LLC | 9.7% of the class | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G/A, by Orca Capital AG | 3.7% of the class | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G/A, by Orca Capital AG | 9.9% of the class | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 3.54% of the class | 5%+ stakes | Source |
| September 19, 2025 | Stake report, Schedule 13G/A, by Orca Capital AG | 4.6% of the class | 5%+ stakes | Source |
| September 18, 2025 | Stake report, Schedule 13G, by Orca Capital AG | 9.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Co-Diagnostics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Co-Diagnostics, Inc. and the records around it.
Co-Diagnostics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Orca Capital AG also filed stake reports on 19 other companies: DarkIris Inc. (Oct 2026), Neo-Concept International Group Holdings Limited (Oct 2026), NFT Limited (Sep 2026)
- Ayrton Capital LLC also filed stake reports on 31 other companies: Bluejay Diagnostics, Inc. (Aug 2026), BTC Digital Ltd. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026)
- JANE STREET GROUP, LLC also filed stake reports on 73 other companies: AXT INC (Nov 2026), BIOVIE INC. (Nov 2026), Bitdeer Technologies Group (Nov 2026)
Watch Co-Diagnostics, Inc.
Get an email when Co-Diagnostics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Co-Diagnostics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Co-Diagnostics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Co-Diagnostics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-04 | In | Executive Vice President | 8-K, 2026-09-04 |
Who leads Co-Diagnostics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Executive Vice President: Daniel Bohrer, appointed (filed 2026-09-04).
New leaders reset buying decisions — get the Full Report on Co-Diagnostics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Executive Vice President at Co-Diagnostics, Inc., with the record behind each one.
Find candidates like Executive Vice President at Co-Diagnostics, Inc.Every change, in the filing's words
Appointed: Daniel Bohrer, Executive Vice President
Effective as of the Separation Date, Daniel Bohrer, the Company's Executive Vice President of Finance and Accounting, will serve as the Company's principal financial officer and principal accounting officer.
- On September 2, 2026, Co-Diagnostics, Inc. (the "Company") and Brian Brown, the Company's Chief Financial Officer, determined that Mr. Brown's last day of employment with the Company would be September 2, 2026 (the "Separation Date").
- Mr. Brown served as the Company's principal financial officer and principal accounting officer through the Separation Date.
- In connection with such appointment, Mr. Bohrer's annual salary was increased from $225,000 to $255,000.
- Mr. Bohrer, age 49, became the Company's Executive Vice President of Finance and Accounting in September 2026.
- From October 2016 through September 2021, Mr. Bohrer served as the Director of Accounting for Workfront, Inc. (acquired by Adobe, Inc. in 2020), a Utah-based software company providing cloud-based work and project management software, where he was responsible for internal and external financial accounting and reporting, technical accounting leadership, equity compensation plan administration, and treasury functions including debt compliance reporting and cash forecasting.
- From January 2014 through October 2016, Mr. Bohrer served as an Assurance Senior Manager at EY, where he provided audit services to various clients in multiple industries.
- Mr. Bohrer holds a Master of Business Administration and Bachelor of Science in Accounting from Utah State University and is a licensed CPA in the State of Utah.
Tools for this story
Each opens in a new tab, filled in for Co-Diagnostics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.